(Q57272427)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28280273%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

title

A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28280273%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28280273%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Jason Li

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28280273%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Ricky W Johnstone

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28280273%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

author name string

S J Vervoort

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28280273%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

R Cole

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28280273%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

A J Rogers

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28280273%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

G P Gregory

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28280273%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

E Vidacs

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28280273%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

R Nagaraja

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28280273%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

K E Yen

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28280273%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

publication date

10 March 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28280273%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28280273%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28280273%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28280273%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

page(s)

1466-1470

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28280273%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2017.84

5 April 2020

exact match

0 references

cites work

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.84

Genomic Classification and Prognosis in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.84

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.84

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.84

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.84

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.84

Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.84

Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.84

Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.84

Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.84

IDH2 inhibition in AML: Finally progress?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.84

Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.84

Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.84

A stem cell molecular signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.84

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.84

21 January 2018

Identifiers

DOI

10.1038/LEU.2017.84

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28280273%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1 reference